Financials
Financial year 2025
PHARMATTOU from Asse, company number BE0793800191, closed financial year 2025 with a result of € 28,691 after tax. For that financial year PHARMATTOU recorded a gross margin of € 38,707 and equity of € 120,675. Compared with financial year 2024, the result moved from € 40,074 to € 28,691. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 16, 2026.
€ 120,675
▲ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 28,691
▼ 28% vs 2024
Profit after tax over the fiscal year.
€ 134,672
▲ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 118,675.
People and assets in 2025
€ 118
▼ 83% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,359
▲ 57% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 18,093
▲ 3% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 13,122 | € 51,614 | € 52,582 | € 38,707 | ▼ 26% |
| Profit after taxes | € 9,470 | € 40,440 | € 40,074 | € 28,691 | ▼ 28% |
| Equity | € 11,470 | € 51,910 | € 91,984 | € 120,675 | ▲ 31% |
| Total debts | € 12,043 | € 33,124 | € 32,698 | € 25,891 | ▼ 21% |
| Cash | € 11,817 | € 80,210 | € 111,666 | € 134,672 | ▲ 21% |
| Retained profit | € 9,470 | € 49,910 | € 89,984 | € 118,675 | ▲ 32% |
| Balance sheet total | € 23,514 | € 85,034 | € 124,682 | € 146,566 | ▲ 18% |
By gross margin, PHARMATTOU ranks 4th of 4 companies with main activity “Detailhandel in farmaceutische producten” in Asse that publish figures (fiscal year 2025).
Key figures of PHARMATTOU, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about PHARMATTOU the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to PHARMATTOU?
What happened at PHARMATTOU in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 28,691 (▼ 28% vs 2024). filed late Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Asse. KBO
In short
From € 9,470 profit in 2022 to € 28,691 profit in 2025.
Paid € 32,967 in corporate taxes since 2022.
Best year ever: 2023, with € 40,440 profit.
Establishments
Establishment units
Physical locations of this company
Jan Tieboutstraat 6
1731 Asse
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Asse
Same main activity (Detailhandel in farmaceutische producten), 3 active companies in Asse, largest first.
€ 415,029 gross margin · 2025
€ 336,913 gross margin · 2025
€ 135,724 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- ATTOU Mohamed Anouar(oprichter) 100%
Details
- Company number
- 0793.800.191
- VAT number
- BE 0793.800.191
- Registered office
- Jan Tieboutstraat 6, 1731 Asse
- Names & denominations
- PHARMATTOU
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 21 November 2022
- Peppol
- Active · Active since 25 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten